Elaine A. Muchmore, of University of California, San Diego, will receive the 2023 Exemplary Service Award from the American Society of Hematology for her exceptional service and dedication to the Society and the field of hematology.
Robert SchreiberElham AziziThe New York Academy of Sciences has announced the winners of the 2024 Innovators in Science Award for their excellence in and commitment to innovative science that has significantly advanced the field of research in cancer immunology.Â
José C. BuenagaKaren EtzkornMichael PelliniKenneth R. StollThe American Cancer Society has named José Buenaga, Karen Etzkorn, Michael Pellini, and Kenneth R. Stoll to its board of directors, with all terms beginning on Jan. 1, 2024.
For many individuals living in the rural 23-county area of North Central Florida served by the UF Health Cancer Center, access to mammography services for breast cancer screening is limited.
The FY24 Defense Appropriations Act is anticipated to provide funding for the BCRP to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for Service Members and their Families, Veterans, and the general public. Â
A study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that Black men diagnosed with more advanced stages of prostate cancer are significantly less likely to be prescribed novel hormone therapy than other racial and ethnic groups—including white or Latino men—despite the therapy being proven to effectively control the growth of prostate tumors and extend the lives of men with the disease.
A report suggests that Lung-MAP, which for almost a decade has undergirded the first NCI-sponsored precision medicine clinical trial in lung cancer, can serve as a model for future clinical research that is more rapid, innovative, and inclusive.
A study of the relationship between the enzyme DDX5, liver cancer and sorafenib, published in the Nature journal Cell Death & Disease points to the potential for a more effective therapy that combines existing anti-cancer drugs with treatments that spur production of this enzyme.
Researchers have developed a method to predict early on which patients with breast cancer are most likely to stop taking potentially life-saving aromatase inhibitor drugs.
FDA approved Jaypirca (pirtobrutinib) for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor and a BCL-2 inhibitor.Â
